91713-54-1

Basic information

• Product Name: Methanone, (2-aMino-5-Methoxyphenyl)(4-chlorophenyl)-
• Synonyms: Methanone, (2-aMino-5-Methoxyphenyl)(4-chlorophenyl)-;[2-AMino-5-(Methyloxy)phenyl](4-chlorophenyl)Methanone;(2-aMino-5-Methoxyphenyl)(4-chlorophenyl)Methanone
• CAS NO: 91713-54-1
• Molecular Formula: C₁₄H₁₂ClNO₂
• Molecular Weight: 261.70358
• Product Categories: Aromatics, Amines, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 91713-54-1.mol
• Article Data: 24

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methanone, (2-aMino-5-Methoxyphenyl)(4-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanone, (2-aMino-5-Methoxyphenyl)(4-chlorophenyl)-(91713-54-1)
• EPA Substance Registry System: Methanone, (2-aMino-5-Methoxyphenyl)(4-chlorophenyl)-(91713-54-1)

Safety Data

• Hazardous Substances Data: 91713-54-1(Hazardous Substances Data)

Usage

Uses

[2-Amino-5-(methyloxy)phenyl](4-chlorophenyl)methanone, can be used in the synthesis of inflammatory agents, such as acetylated histones mimic compound, and 2-amino-3-benzoylphenylacetic acid and analogs.

Upstream product

• 38527-50-3 2-methyl-6-(methoxy)-3,1-benzoxazin-4-one 
• 37795-77-0 6-methoxy-2H-3,1-benzoxazine-2,4(1H)-dione 
• 214971-09-2 2-amino-5,N-dimethoxy-N-methylbenzamide 
• 106-39-8 bromochlorobenzene 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 873-77-8 (4-chlorphenyl)magnesium bromide 

Downstream Products

• 1300090-44-1 phenylmethyl (1-(1H-1,2,3-benzotriazol-1-yl)-2-{[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]amino}-2-oxoethyl)carbamate 
• 1300019-46-8 (S)-methyl 2-(5-(4-chlorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetate 
• 1300019-43-5 (S)-methyl 2-(5-(4-chlorophenyl)-7-methoxy-2-thioxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetate 
• 1300019-41-3 methyl 2-[(3S,2Z)-2-(acetylhydrazono)-5-(4-chlorophenyl)-7-(methyloxy)-1,3-dihydro-1,4-benzodiazepin-3-yl]acetate 
• 1300019-40-2 methyl 2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzol[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate 
• 1300019-38-8 [(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid 
• 1300019-50-4 1,1-dimethylethyl [5-({[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetyl}amino)pentyl]carbamate 
• 1300019-52-6 N-(5-aminopentyl)-2-[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetamide trifluoroacetate 
• 1300019-48-0 methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate 
• 1449372-95-5 3-acetyl-4-(4-chlorophenyl)-6-methoxyquinolin-2(1H)-one 
• 1449373-77-6 4-(4-chlorophenyl)-3-[5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]-6-methoxyquinolin-2(1H)-one 
• 1449374-24-6 4-{5-(4-chlorophenyl)-3-[4-(4-chlorophenyl)-6-methoxy-2-oxo-1,2-dihydroquinolin-3-yl]-4,5-dihydro-1H-pyrazol-1-yl}-4-oxobutanoic acid 
• 1449374-32-6 (Z)-4-{3-[4-(4-bromophenyl)-2-oxo-1,2-dihydroquinolin-3-yl]-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl}-4-oxobut-2-enoic acid 
• 1449373-32-3 (E)-4-(4-chlorophenyl)-3-[3-(4-chlorophenyl)acryloyl]-6-methoxyquinolin-2(1H)-one 

Relevant articles and documents

THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE

The present application is directed to a therapeutic composition, comprising two precursor compounds (monomers) that are suitable for assembly via two or more reversible covalent bonds. The monomers are polyfunctionalized molecules comprising a bioorthogo

Evaluation of linker length effects on a BET bromodomain probe

Fueled by the therapeutic potential of the epigenetic machinery, BET bromodomains have seen high interest as drug targets. Herein, we introduce different linkers to a BET bromodomain benzodiazepine ligand (I-BET762) to gauge its implications in the develo

NOVEL PROCESS

A compound or a pharmaceutically acceptable salt or solvate thereof with a molecular weight in the range 100 to 750 which inhibits the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner which is able to: a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at: or b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at and c) which are also able to form a Van der Waals interaction with a lipophilic binding region of a binding pocket such that one or more heavy atoms of the said compounds lie within a 5A range of any of the heavy atoms of the following bromodomain residues which define the binding pocket: for use in the treatment of chronic autoimmune and inflammatory conditions, acute inflammatory conditions or cancer.